FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2757243772> ?p ?o ?g. }

• W2757243772 endingPage "382" @default.
• W2757243772 startingPage "366" @default.
• W2757243772 abstract "OBJECTIVE Stereotactic radiosurgery (SRS) is the primary modality for treating brain metastases. However, effective radiosurgical control of brain metastases ≥ 2 cm in maximum diameter remains challenging and is associated with suboptimal local control (LC) rates of 37%–62% and an increased risk of treatment-related toxicity. To enhance LC while limiting adverse effects (AEs) of radiation in these patients, a dose-dense treatment regimen using 2-staged SRS (2-SSRS) was used. The objective of this study was to evaluate the efficacy and toxicity of this treatment strategy. METHODS Fifty-four patients (with 63 brain metastases ≥ 2 cm) treated with 2-SSRS were evaluated as part of an institutional review board–approved retrospective review. Volumetric measurements at first-stage stereotactic radiosurgery (first SSRS) and second-stage SRS (second SSRS) treatments and on follow-up imaging studies were determined. In addition to patient demographic data and tumor characteristics, the study evaluated 3 primary outcomes: 1) response at first follow-up MRI, 2) time to local progression (TTP), and 3) overall survival (OS) with 2-SSRS. Response was analyzed using methods for binary data, TTP was analyzed using competing-risks methods to account for patients who died without disease progression, and OS was analyzed using conventional time-to-event methods. When needed, analyses accounted for multiple lesions in the same patient. RESULTS Among 54 patients, 46 (85%) had 1 brain metastasis treated with 2-SSRS, 7 patients (13%) had 2 brain metastases concurrently treated with 2-SSRS, and 1 patient underwent 2-SSRS for 3 concurrent brain metastases ≥ 2 cm. The median age was 63 years (range 23–83 years), 23 patients (43%) had non–small cell lung cancer, and 14 patients (26%) had radioresistant tumors (renal or melanoma). The median doses at first and second SSRS were 15 Gy (range 12–18 Gy) and 15 Gy (range 12–15 Gy), respectively. The median duration between stages was 34 days, and median tumor volumes at the first and second SSRS were 10.5 cm 3 (range 2.4–31.3 cm 3 ) and 7.0 cm 3 (range 1.0–29.7 cm 3 ). Three-month follow-up imaging results were available for 43 lesions; the median volume was 4.0 cm 3 (range 0.1–23.1 cm 3 ). The median change in volume compared with baseline was a decrease of 54.9% (range −98.2% to 66.1%; p < 0.001). Overall, 9 lesions (14.3%) demonstrated local progression, with a median of 5.2 months (range 1.3–7.4 months), and 7 (11.1%) demonstrated AEs (6.4% Grade 1 and 2 toxicity; 4.8% Grade 3). The estimated cumulative incidence of local progression at 6 months was 12% ± 4%, corresponding to an LC rate of 88%. Shorter TTP was associated with greater tumor volume at baseline (p = 0.01) and smaller absolute (p = 0.006) and relative (p = 0.05) decreases in tumor volume from baseline to second SSRS. Estimated OS rates at 6 and 12 months were 65% ± 7% and 49% ± 8%, respectively. CONCLUSIONS 2-SSRS is an effective treatment modality that resulted in significant reduction of brain metastases ≥ 2 cm, with excellent 3-month (95%) and 6-month (88%) LC rates and an overall AE rate of 11%. Prospective studies with larger cohorts and longer follow-up are necessary to assess the durability and toxicities of 2-SSRS." @default.
• W2757243772 created "2017-10-06" @default.
• W2757243772 creator A5014057367 @default.
• W2757243772 creator A5021893710 @default.
• W2757243772 creator A5029857725 @default.
• W2757243772 creator A5035416012 @default.
• W2757243772 creator A5039448543 @default.
• W2757243772 creator A5042834030 @default.
• W2757243772 creator A5048431132 @default.
• W2757243772 creator A5058440874 @default.
• W2757243772 creator A5065263618 @default.
• W2757243772 creator A5065809428 @default.
• W2757243772 creator A5068403922 @default.
• W2757243772 creator A5079216912 @default.
• W2757243772 creator A5085460226 @default.
• W2757243772 creator A5087295298 @default.
• W2757243772 date "2018-08-01" @default.
• W2757243772 modified "2023-10-10" @default.
• W2757243772 title "Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm" @default.
• W2757243772 cites W1484195756 @default.
• W2757243772 cites W1508643692 @default.
• W2757243772 cites W1553610304 @default.
• W2757243772 cites W1583489867 @default.
• W2757243772 cites W1653443644 @default.
• W2757243772 cites W1702197803 @default.
• W2757243772 cites W1872520013 @default.
• W2757243772 cites W1964502989 @default.
• W2757243772 cites W1967467401 @default.
• W2757243772 cites W1974820090 @default.
• W2757243772 cites W1974986320 @default.
• W2757243772 cites W1978575247 @default.
• W2757243772 cites W1980048431 @default.
• W2757243772 cites W1986254095 @default.
• W2757243772 cites W2001198784 @default.
• W2757243772 cites W2003917401 @default.
• W2757243772 cites W2004038246 @default.
• W2757243772 cites W2004852620 @default.
• W2757243772 cites W2008153607 @default.
• W2757243772 cites W2013843382 @default.
• W2757243772 cites W2015902877 @default.
• W2757243772 cites W2016693307 @default.
• W2757243772 cites W2018952014 @default.
• W2757243772 cites W2019607817 @default.
• W2757243772 cites W2035147135 @default.
• W2757243772 cites W2038247960 @default.
• W2757243772 cites W2047930883 @default.
• W2757243772 cites W2059734719 @default.
• W2757243772 cites W2062181254 @default.
• W2757243772 cites W2069289885 @default.
• W2757243772 cites W2073005838 @default.
• W2757243772 cites W2074010027 @default.
• W2757243772 cites W2076229598 @default.
• W2757243772 cites W2077393061 @default.
• W2757243772 cites W2083128109 @default.
• W2757243772 cites W2084420331 @default.
• W2757243772 cites W2087741473 @default.
• W2757243772 cites W2090548981 @default.
• W2757243772 cites W2091621737 @default.
• W2757243772 cites W2104165122 @default.
• W2757243772 cites W2115846740 @default.
• W2757243772 cites W2122586261 @default.
• W2757243772 cites W2128871519 @default.
• W2757243772 cites W2129582022 @default.
• W2757243772 cites W2131266864 @default.
• W2757243772 cites W2143843774 @default.
• W2757243772 cites W2144534181 @default.
• W2757243772 cites W2146269545 @default.
• W2757243772 cites W2157216324 @default.
• W2757243772 cites W2157582515 @default.
• W2757243772 cites W2158628168 @default.
• W2757243772 cites W2158757066 @default.
• W2757243772 cites W2158789700 @default.
• W2757243772 cites W2159314579 @default.
• W2757243772 cites W2163467607 @default.
• W2757243772 cites W2163887411 @default.
• W2757243772 cites W2164157068 @default.
• W2757243772 cites W2167270572 @default.
• W2757243772 cites W2169943019 @default.
• W2757243772 cites W2177244913 @default.
• W2757243772 cites W2259606385 @default.
• W2757243772 cites W2292305777 @default.
• W2757243772 cites W2302127234 @default.
• W2757243772 cites W2318289274 @default.
• W2757243772 cites W2329793926 @default.
• W2757243772 cites W2395922855 @default.
• W2757243772 cites W2410703300 @default.
• W2757243772 cites W2415633845 @default.
• W2757243772 cites W2460924712 @default.
• W2757243772 cites W2464028256 @default.
• W2757243772 cites W2468720884 @default.
• W2757243772 cites W2492450141 @default.
• W2757243772 cites W4362225197 @default.
• W2757243772 doi "https://doi.org/10.3171/2017.3.jns162532" @default.
• W2757243772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28937324" @default.
• W2757243772 hasPublicationYear "2018" @default.
• W2757243772 type Work @default.
• W2757243772 sameAs 2757243772 @default.
• W2757243772 citedByCount "75" @default.

• next